Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2Lymphoid 2Other hematologic neoplasm 1Head & Neck 1

Conditions

Neoplasms 1Lymphoma 1Hematologic Neoplasms 1

Interventions

Cytarabine 905Cyclophosphamide 899fludarabine 525venetoclax 489fludarabine phosphate 468Azacitidine 460Rituximab 431Methotrexate 419Etoposide 320Filgrastim 299Busulfan 296Dexamethasone 286Vincristine 285Daunorubicin 283Peripheral Blood Stem Cell Transplantation 258Whole-Body Irradiation 243Mycophenolic Acid 232Decitabine 230Granulocyte Colony-Stimulating Factor 227Tacrolimus 220Imatinib Mesylate 211Idarubicin 205Melphalan 202Cyclosporine 182Doxorubicin 177Radiotherapy 169Prednisone 163Dasatinib 163Mitoxantrone 161Lenalidomide 160

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
TAK-981 × Other hematologic neoplasm × Clear all
NCT03648372 2024-11-19

A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System

Takeda

Phase 1/2 Terminated
109 enrolled 54 charts
LymphoidOther hematologic neoplasm

Lymphoma, Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡